immune oncology vs. targeted therapies in solid tumors is ... · tremelimumab fully human igg2...
Post on 21-Jul-2020
5 Views
Preview:
TRANSCRIPT
Immune oncology vs. targeted
therapies in solid tumors –
is there a winner?
Dr. Răzvan CurcăSpitalul Judeţean de Urgenţă Alba-Iulia
Evolution of Cancer Therapy:
Core Treatment Modalities
DeVita VT Jr, et al. Cancer Res. 2008;68:8643–8653; American Cancer Society.
http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/; Hodi FS, et al. N Engl J Med.
2010;363:711–723; Sznol M, et al. Presented at ASCO 2013: oral presentation; Kantoff PW, et al. N Engl J
Med. 2010;363:411–422; Finn OJ. Ann Oncol. 2012;23(suppl 8):viii6–viii9.
Surgery
1846
Radiation Therapy
1901
Chemotherapy
1946
Targeted Therapy
1997
Immuno-Oncology
2011
Targeted therapy
Prototype- CML
FDA approved targeted therapies
FDA approved targeted therapies (2)
“FDA approves Zykadia for late-
stage lung cancer”
April 29, 2014- FDA granted accelerated
approval to Zykadia (ceritinib) for patients
with metastatic ALK-positive NSCLC
previously treated with crizotinib based on
phase I trial data
“Today’s approval illustrates how a
greater understanding of the underlying
molecular pathways of a disease can lead
to the development of specific therapies
aimed at these pathways,” Richard Pazdur
About OnCompass
ONCOMPASS™ Full tests the
following 58 genes: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R,
CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2,
FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2,
JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1,
NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4,
SMARCB1, SMO, SRC, STK11, TP53, VHL,DDR2, CHEK2, PIK3R1,
MAP2K1, JAK1, TGFBR2, PDGFRB, IGFR1, and 3 FISH test from the
followings: HER-2, ALK, c-MET, FGFR1, PIK3CA, EGFR, ROS-1
A list of globally available clinical trials is
also provided.
Molecular tumor boardUniversity of California San Diego
Moores Cancer Center Experience
Includes clinicians, basic scientists,
geneticists and bioinformaticians
34 pretreated pts. included, with a median
of 3 prevous therapies
Median time to test result= 27 days (14-
77 days)
NGS techniques were used (182 or 236
gene panels)
Schwaederle M, Parker BA, Schwab RB, et al. Molecular tumor board: the University of California-San Diego
Moores Cancer Center experience. Oncologist. 2014;19:631-636.
Molecular tumor boardUniversity of California San Diego
Moores Cancer Center Experience
Median number of
molecular
abnormalities by
NGS= 4 (1-14)
No two pts. had the
same abnormalities
107 of them seen only
once
Schwaederle M, Parker BA, Schwab RB, et al. Molecular tumor board: the University of California-San Diego
Moores Cancer Center experience. Oncologist. 2014;19:631-636.
Molecular tumor boardUniversity of California San Diego
Moores Cancer Center Experience
11 evaluable pts. with treatment informed by
molecular diagnosis
3 PRs (PFS 3.4 mo, >6.5 mo and 7.5 mo)
Most common reasons for not receiving
molecular-driven treatment:
◦ Ineligible for clinical trial
◦ Could not travel to trial center
◦ Insurance not cover the cognate agents
Schwaederle M, Parker BA, Schwab RB, et al. Molecular tumor board: the University of California-San Diego
Moores Cancer Center experience. Oncologist. 2014;19:631-636.
Resistance ultimately emerges…
Drug resistance to targeted therapies: déjà vu all over again. Groenendijk FH, Bernards R.
Mol Oncol. 2014 Sep 12;8(6):1067-83.
38-year-old man with BRAF-mutated melanoma
Patient discontinued vemurafenib therapy, but continued to have rapid disease progression and died several weeks later.
Wagle N, et al. J Clin Oncol 2011;29:3085–96
Baseline 15 weeks of
vemurafenib
23 weeks of
vemurafenib
Strategies to overcome resistance
Drug resistance to targeted therapies: déjà vu all over again. Groenendijk FH, Bernards R.
Mol Oncol. 2014 Sep 12;8(6):1067-83.
RAS pathway super-inhibition
C. Robert et. al. ESMO 2014
Romanian-derived perspective on
future of targeted therapy
SHIVA- proof of concept trial
SHIVA- proof of concept trial
SHIVA- proof of concept trial
SHIVA- proof of concept
randomized trial
Immuno-Oncology
Active immunotherapy
Adoptive cell transfer
immunotherapy
IL-2
IFN
IL-15
IL-21
Peptide vaccine
DC vaccine
Genetic vaccine
OX40
CD137
CD40
PD-1
CTLA-4
T cell cloningTCR or CAR
genetic engineering
General Approaches for
Cancer Immunotherapy
Pts at Risk, n
Ipilimumab 1861 839 370 254 192 170 120 26 15 5 0
Pro
po
rti
on
Alive
0
0.2
0.4
0.6
0.8
1.0
Mos
0 12 24 36 48 60 72 84 96 108 120
Median OS: 11.4 mos (95% CI: 10.7-12.1)
Ipilimumab
Censored
Hodi S, et al. 2013 European Cancer Congress. Abstract LBA 24. Schadendorf D, et al. J Clin Oncol. 2015
Ipilimumab: Pooled Survival Analysis From
Phase II/III Trials in Advanced Melanoma
3-yr OS rate: 22% (95% CI: 20-24)
Clinical Development of Anti–PD-1
Checkpoint Inhibitors in Solid Tumors
Antibody Molecule Development Stage
NivolumabFully
human IgG4
Approved (US): advanced melanoma after previous therapy, advanced NSCLC
after CTPhase III multiple tumors (NSCLC,
melanoma, RCC, HNSCC, GBM, gastric)
PembrolizumabHumanized
IgG4
Approved (US): advanced melanoma after previous therapy
Phase III multiple tumors (HNSCC, NSCLC, melanoma, bladder, gastric/GE)
PidilizumabHumanized
IgG1 Phase II multiple tumors (pancreatic,
CRC, RCC, prostate, CNS)
AMP-224Fc-PD-L2
fusion protein
Phase I
Clinical Development of Anti–PD-1
Checkpoint Inhibitors in Solid Tumors
Antibody Molecule Development Stage
Atezolizumab(MPDL3280A)
Engineered human
IgG1
Phase III multiple tumors (NSCLC, bladder, RCC, TNBC)
Avelumab(MSB0010718C)
Fully human
IgG1Phase III (NSCLC)
Durvalumab(MEDI4736)
Engineeredhuman
IgG1
Phase III multiple tumors (NSCLC, HNSCC)
Clinical Development of Other Immune
Checkpoint Inhibitors in Solid Tumors
Target Antibody Molecule Development Stage
CTLA-4
IpilimumabHumanized
IgG1
Approved: advanced melanomaPhase III multiple tumors
(melanoma, NSCLC, SCLC, CRPC, GBM, RCC)
TremelimumabFully
human IgG2
Phase III multiple tumors (HNSCC, NSCLC)
IDO
INCB024360 TKIPhase II multiple tumors
(ovarian, melanoma)
NLG919 TKI Phase I
B7-H3 MGA271Humanized IgG1kappa
Phase I
LAG-3 BMS-986016 --- Phase I
Mutational load in different tumors
Alexandrov et al. Nature 500, 415–42: 22 August 2013
Management of Cancer in the
Post Anti–PD-1/PD-L1 Era
Anti–PD-1/anti–PD-L1
Generate T cells:
+ Anti–CTLA-4
+ Immune-activating
antibodies or cytokines
+ TLR agonists or oncolytic
viruses
+ IDO or macrophage
inhibitors
+ Targeted therapies
Bring T cells
into tumors:
Vaccines
TCR-engineered ACT
CAR-engineered ACT
CheckMate 067: Improved PFS with
Nivo + Ipi or Nivo Alone vs Ipi Alone
Larkin J, et al. N Engl J Med. 2015; [epub ahead of print].
1.00.9
0.8
0.7
0.6
0.5
0.4
0.3
0.1
0
0.2Pro
po
rtio
n A
live a
nd
Pro
gre
ss
ion
Fre
e
Nivo + Ipi
Nivo
Ipi
*Stratified log-rank P < .00001 vs Ipi.†Exploratory endpoint. Study not powered to detect a statistical difference between Nivo + Ipi and Nivo.
Mos0 3 6 9 12 15 16 21
Nivo + Ipi(n = 314)
Nivo(n = 316)
Ipi(n = 315)
Median PFS, mos (95% CI)
11.5(8.9-16.7)
6.9(4.3-9.5)
2.9(2.8-3.4)
HR (99.5% CI) vs Ipi 0.42(0.31-0.57)*
0.57(0.43-0.76)*
_
HR (95% CI) vs Nivo 0.74(0.60-0.92)†
_ _
Conclusion
Targeted therapy has now much more data
and clinical applications than immunotherapy
Targeted therapy drugs have great success in
some cases, but many times resistence will
emerge and the treatment ultimately will fail
Rational combinations of targeted therapy
could improve outcome, but the expected
benefit is still limited
Conclusion
Targeted immunotherapy comes with high
hopes for curing cancer
Experience with immuno-oncology is till
now very promising, but not offering
certainties for most cancer patients
A minority of patients could achieve long
term complete remissions, which are more
or less equivalent with cure
Biomarkers for identifying responding
patients are currently under investigation
Conclusion
Combinations of targeted immune-therapy
with other weapons from therapeutic
armametarium (like chemotherapy,
radiotherapy and even classical targeted
therapy) are eagerly awaited and currently
under broad investigation
Final conclusion
There is not clear winner till now, only high
hopes.
top related